A phase 1 open-label single-radiolabeled dose study to investigate the absorption, metabolism and excretion of [14C] PD 0332334 [PD-332334] in six healthy male volunteers.

Trial Profile

A phase 1 open-label single-radiolabeled dose study to investigate the absorption, metabolism and excretion of [14C] PD 0332334 [PD-332334] in six healthy male volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2010

At a glance

  • Drugs Imagabalin (Primary)
  • Indications Generalised anxiety disorder
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Nov 2008 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 21 Jan 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
    • 16 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top